Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world

OBJECTIVE: To assess the efficacy and safety of iGlarLixi (titratable fixed-ratio combination of insulin glargine (iGlar) and lixisenatide) in patients with type 2 diabetes (T2D) living in North America (NA; USA and Canada) compared with the rest of the world (RoW). RESEARCH DESIGN AND METHODS: Post...

Descripción completa

Detalles Bibliográficos
Autores principales: Dailey, George, Bajaj, Harpreet S, Dex, Terry, Groleau, Melanie, Stager, William, Vinik, Aaron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Emerging Technologies, Pharmacology and Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501856/
https://www.ncbi.nlm.nih.gov/pubmed/31114694
http://dx.doi.org/10.1136/bmjdrc-2018-000581

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501856/
https://www.ncbi.nlm.nih.gov/pubmed/31114694
http://dx.doi.org/10.1136/bmjdrc-2018-000581

Ejemplares similares